Stock listing
Lumosa Therapeutics Co Ltd
Selected listing: 6535 · TPEX · TWD · TW
Lumosa Therapeutics Co Ltd (TPEx:6535), Health Technology. Latest release Feb 6, 2026: LT3001 DEMONSTRATES FUNCTIONAL IMPROVEMENTS IN PATIENTS WITH DISABLING…
- Ticker
- TPEx:6535
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- TPEx
- Currency
- TWD
About Lumosa Therapeutics Co Ltd
The company focuses on developing innovative therapies to address unmet medical needs. Lumosa is committed to advancing its research and development efforts in the biopharmaceutical sector.
Latest news from Lumosa Therapeutics Co Ltd
LT3001 DEMONSTRATES FUNCTIONAL IMPROVEMENTS IN PATIENTS WITH DISABLING ACUTE ISCHEMIC STROKE
February 6, 2026
LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE
October 28, 2025
Lumosa Therapeutics : Board Approved the Revised Exclusive Licensing Agreement for the Veterinary Analgesic
August 9, 2022
Lumosa Therapeutics : Board Approved the Binding Term Sheet for LT1001, a Long-acting Analgesic Injection, with a Pakistani Pharmaceutical Company
August 9, 2022
Lumosa Therapeutics : Board of Directors approved the Cancellation of Restricted Shares to Employees Stock Awards
August 9, 2022
Research Lumosa Therapeutics Co Ltd
Lumosa Therapeutics Co Ltd company profile
View the public company page for Lumosa Therapeutics Co Ltd on 6ix.
Lumosa Therapeutics Co Ltd news
Read company news and market updates connected to Lumosa Therapeutics Co Ltd.
Lumosa Therapeutics Co Ltd investor events
Find investor webinars, events, and replay context for Lumosa Therapeutics Co Ltd.